On June 3, the US FDA approved an Investigative New Drug (IND) application for IC14 together with remdesivir in 300 COVID-19 patients at risk of acute respiratory distress syndrome (ARDS).
The Company expects to be able to announce details of the sponsorship of these breakthrough clinical studies during March 2021.
“IC14 represents a novel and exciting approach to the prevention and treatment of the cytokine storm that is the most common event leading to death in this new pandemic coronavirus. As such, it has the potential to transform treatment of the most frightening health crisis of this Century. “
Garry Redlich, CEO